Designmedix, Inc.

Portland, OR 97201

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $5.47MM
First Award Date 03/15/07
Most Recent Award Date 04/01/16

Key Personnel

Last Name Name Awards Contact
Burgess Steven Burgess 1
Peyton David H Peyton 9
ECKMANN LARS ECKMANN 1

10 Awards Won

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-124
Budget: 04/01/16 - 03/31/17

DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. This project carries on preclinical...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 02/04/16 - 01/31/17

? DESCRIPTION (provided by applicant): Trichomonas vaginalis is the causative agent of the most common, non-viral sexually-transmitted infection with ~250 million new cases reported annually in the world and 5-7 million cases in the U.S. In addition to infections of the urogenital tract, trichomoniasis increases the risk of adverse pregnancy ...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-124
Budget: 04/01/15 - 03/31/16

DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. This project carries on preclinical...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-124
Budget: 04/15/14 - 03/31/15

DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. This project carries on preclinical...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-113
Budget: 09/05/12 - 02/28/13

DESCRIPTION (provided by applicant): There is a great need for anti-malarial drugs that are inexpensive and effective against drug-resistant strains. Malaria is one of the most important diseases worldwide, with over 225 million cases each year, and about 800 thousand deaths. Most of these deaths occur in sub-Saharan Africa among the more vulner...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-10-124
Budget: 09/01/12 - 08/31/13

DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative new class of potent antimalarials designed to overcome drug resistance. We have developed an or...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-10-124
Budget: 09/01/11 - 08/31/12

DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative new class of potent antimalarials designed to overcome drug resistance. We have developed an or...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 04/01/10 - 03/31/13

DESCRIPTION (provided by applicant): DesignMedix has developed a novel class of compounds to address the pressing need for an orally available, inexpensive drug to counter the spread of chloroquine-resistant malaria. Preliminary data showed that this novel class of molecules, called "reversed chloroquines" (RCQs), acts against both chloroquine- ...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 04/01/09 - 03/31/10

DESCRIPTION (provided by applicant): DesignMedix has developed a novel class of compounds to address the pressing need for an orally available, inexpensive drug to counter the spread of chloroquine-resistant malaria. Preliminary data showed that this novel class of molecules, called "reversed chloroquines" (RCQs), acts against both chloroquine- ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-35
Budget: 03/15/07 - 02/28/09

DESCRIPTION (provided by applicant): The intent of the work presented in this proposal is to counter the worldwide health problem brought on by the spread of chloroquine-resistant malaria. To address the need for an orally available and inexpensive replacement drug, we have developed a novel class of molecules called "reversed chloroquines" (RCQ...

Load More